Werewolf Therapeutics, Inc. (HOWL): Long-Term Debt
$32.09M
As of 2025-12-31
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.09M | 0.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $32.09M | -19.8% | 2025-03-11, Balance as of period end |
| 2023-12-31 | $40.00M | n/a | 2024-03-07, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $32.09M | 0.0% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $15.30M | 0.0% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $60.04M | -4.2% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $10.16M | -4.1% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| Scienture Holdings, Inc. (SCNX) | 2024-12-31 | $2.90M | n/a |
| Spruce Biosciences, Inc. (SPRB) | 2024-12-31 | $1.84M | -50.4% |
| Eton Pharmaceuticals, Inc. (ETON) | 2024-12-31 | $29.81M | n/a |
| Journey Medical Corp (DERM) | 2025-12-31 | $25.28M | +1.6% |
Compare HOWL, ALDX, NWBO, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗